|Bid||13.42 x 800|
|Ask||13.45 x 800|
|Day's range||13.11 - 13.65|
|52-week range||10.81 - 21.86|
|Beta (5Y monthly)||1.28|
|PE ratio (TTM)||N/A|
|Earnings date||04 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||23.79|
Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.
Key Insights Institutions' substantial holdings in Intercept Pharmaceuticals implies that they have significant...
Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.